Scalper1 News
Biotech PTC Therapeutics’ (PTCT) muscular-dystrophy drug got a surprise recommendation from a European Union panel Friday, sending the stock up 50% in early afternoon trading on the stock market. Earlier, the stock rose more than 70%. The Committee for Medicinal Products for Human Use (CHMP), the advisory panel of the European Medicines Agency, recommended conditional approval of PTC’s drug Translarna for patients with Duchenne muscular dystrophy Scalper1 News
Scalper1 News